GABRA4
Gamma-aminobutyric acid receptor subunit alpha-4
As of the edition of 20 October 2026, GABRA4 (gamma-aminobutyric acid receptor subunit alpha-4, UniProt P48169) has 3 drugs tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P48169
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Nervous system; Mental health; Inherited and neonatal; Lungs and airways; Cancer; Heart and blood vessels; Hormones
- Registered trials of its drugs
- 39
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Zopiclone | Marketed | Phase 4 | none listed |
| Gaboxadol | Stopped | Phase 3 | none listed |
| Meprobamate | Marketed | No phase stated | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 1 |
| Total on the list | 3 |
The other 1 company at GABRA4
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at GABRA4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.